Hyphens Pharma International Ltd. 1J5
SGX · Singapore · Health Technology
SGD 0.3700+0.01 (+1.37%)
Market closed· · SGD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SGD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Even if it's not a huge purchase, we think it was good to see that See Wah Lim, the Executive Chairman & CEO of Hyphens...
The market was pleased with the recent earnings report from Hyphens Pharma International Limited ( Catalist:1J5...
Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that it has granted the rights to commercialise its innovative product, Cerapro® MED Skin Barrier Cream, to Louis Widmer SA ("Louis Widmer") via a licensing, supply and commercialisation agreement ("Out-Licensing Agreement") that covers six European countries, namely Switzerla
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.